Press releases
Galenica increases sales growth in the third quarter
Ad hoc announcement pursuant to Art. 53 LR, Thursday, 24 October 2024
Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%, IQVIA, pharmaceutical market Switzerland, YTD September 2024).
Expansion of the Executive Committee and handover of the position of CFO
Press release, Tuesday, 6 August 2024
Galenica is aligning its pharmacy business to an even greater focus on customers. With Stephan Mignot, Marketing for the pharmacies will have a direct seat on the Executive Committee. In addition, the two strategic growth areas “Products & Brands” and “Home Care” are being merged into a single unit under the management of Thomas Szuran for focused expansion. The changes will enter into force on 1 September 2024. The long-standing CFO Felix Burkhard has decided to leave the company at the end of 2024 to embark on a new phase of his professional life. He will retain and continue his role as Chair of the Board of Trustees of the Galenica Pension Fund. Julian Fiessinger will succeed him as CFO from 1 January 2025. Julian Fiessinger has headed “Investor Relations & Corporate Finance” at Galenica since 2021 and knows the financial market and the company inside out.
Galenica achieves solid growth in a challenging market environment
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 6 August 2024
Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamically than the market.